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 19 
ABSTRACT 20 
 21 
Lipophilic copper (Cu)-containing complexes have shown promising antibacterial activity 22 
against a range of bacterial pathogens. To examine the susceptibility of the intracellular human 23 
pathogen Chlamydia trachomatis to copper complexes containing bis(thiosemicarbazone) 24 
ligands [Cu(btsc)], we tested the in vitro effect of CuII-diacetyl- and CuII-glyoxal-bis[N(4)-25 
methylthiosemicarbazonato] (Cu(atsm) and Cu(gtsm), respectively) on C. trachomatis. 26 
Cu(atsm) and to a greater extent, Cu(gtsm), prevented the formation of infectious chlamydial 27 
progeny. Impacts on host cell viability and respiration were also observed in addition to the 28 
Chlamydia impacts. This work suggests that copper-based complexes may represent a new lead 29 
approach for future development of new therapeutics against chlamydial infections, although 30 
host cell impacts need to be fully explored.  31 
 32 
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 40 
Chlamydia trachomatis is the most common sexually transmitted bacterial infection 41 
worldwide. As an obligate intracellular bacterial pathogen, Chlamydia has a unique 42 
developmental cycle that consists of an extracellular, non-replicative, infectious form 43 
(elementary body) and an intracellular, replicative form (reticulate body). Chlamydia relies 44 
heavily on the host for nutrition and energy and ATP/ADP transporters have been identified. 45 
Yet, metabolic data has demonstrated that Chlamydia is capable of generating energy through 46 
substrate level phosphorylation and oxidative phosphorylation with a respiratory chain 47 
terminating in a cytochrome bd oxidase (reviewed in (Omsland et al., 2014)). 48 
Chlamydia infections are currently treated with 1 g of azithromycin. In some cases, a 49 
seven day doxycycline regimen is used, although this is less preferred as non-compliance can 50 
result in the induction of chlamydial persistence and treatment failure. The increasing 51 
prevalence of Neisseria gonorrhoeae co-infections and a rise in resistance (or reduced 52 
susceptibility) of gonococcus to azithromycin suggests that more effective combination 53 
treatments that target both pathogens are needed. In this context, recent work has identified 54 
that small and lipophilic copper complexes are highly effective against N. gonorrhoeae, 55 
including multidrug-resistant strains (Djoko et al., 2012, Djoko et al., 2014, Djoko et al., 56 
2015).  57 
Copper is essential for bacterial metabolism but it is bacteriotoxic in excess. The 58 
antimicrobial properties of excess copper ions have been documented for centuries. Copper 59 
primarily poisons bacteria by displacing other metal ions in metalloproteins and inactivating 60 
key bacterial metabolic pathways (Macomber & Imlay, 2009). In the pre-antibiotic age, ionic 61 
copper salts were used to control bacterial infections but due to poor membrane permeability, 62 
there was a high dose requirement. Recently, we and others have explored the use of small, 63 
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lipophilic ligands or pro-ligands to facilitate delivery of copper ions across bacterial 64 
membranes (termed as “copper ionophores”) (Speer et al., 2013, Festa et al., 2014, Haeili et 65 
al., 2014, Shah et al., 2016). These copper ionophores are effective against a variety of 66 
pathogens, including Mycobacterium tuberculosis and Staphylococcus aureus (Speer et al., 67 
2013, Haeili et al., 2014, Shah et al., 2016). Of interest to this work are copper ionophores 68 
containing bis(thiosemicarbazonato) ligands (Cu(btsc)s) such as CuII-diacetyl- and CuII-69 
glyoxal-bis[N(4)-methylthiosemicarbazonato] (Cu(atsm) and Cu(gtsm), respectively) (Figure 70 
1A), which showed activity in vitro against N. gonorrhoeae (Djoko et al., 2014, Djoko et al., 71 
2015). It has previously been established that copper ions will inhibit Chlamydia if added 72 
prior to cellular entry, and some reports indicate that women using copper intrauterine 73 
devices as a contraceptive may have a lower frequency of contracting Chlamydia (Kleinman 74 
et al., 1989). To evaluate if copper ionophores could also be effective against Chlamydia, we 75 
tested the in vitro effect of Cu(gtsm) and Cu(atsm) on Chlamydia trachomatis.  76 
Cu(btsc) complexes were added to Chlamydia trachomatis serovar D/UW-3/Cx 77 
cultures (in McCoy B cells) at the mid-replicative phase (20 h PI). Cu(atsm) and Cu(gtsm) 78 
were provided as powders by Dr Paul Donnelly from The University of Melbourne (Gringras 79 
et al., 1962, Paterson & Donnelly, 2011). Cultures were propagated using standard conditions 80 
at a multiplicity of infection of 1 (Huston et al., 2008). The compounds were left in the 81 
cultures until the conclusion of the developmental cycle and cultures were harvested and re-82 
infected onto fresh McCoy B monolayers to enumerate infectious progeny (previously 83 
described protocols (Huston et al., 2007, Huston et al., 2008, Lawrence et al., 2016)). The 84 
compounds were highly effective with a loss of infectious progeny detected at the low 85 
micromolar range for both compounds (Figure 1B). The Cu(gtsm)  had a greater impact on 86 
chlamydial infectious progeny production (1.6 µM), compared to Cu(atsm) (3.2 µM, Figure 87 
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1B). Note that 10e3 is the limitation of detection for this assay as the number of IFU below 88 
this threshold cannot be reliably quantified. 89 
The elementary body (EBs) does not undergo cellular division, but does have 90 
metabolic activity (Omsland et al., 2012). To evaluate whether the Cu(btsc) complexes are 91 
also effective against the elementary body, we incubated elementary bodies with each 92 
compound in Sucrose Phosphate Glutamate (SPG) media for 30 mins, washed, and 93 
immediately added to a McCoy B cell monolayer to commence a chlamydial infection. The 94 
infectious progeny formed from this infection were then enumerated. The treatment of 95 
elementary bodies was effective, although almost 50x higher dose (50 µM) (compared to 96 
treatment of the intracellular Reticulate body (RB) phase; Figure 1C). As was the case during 97 
the intracellular growth phase, Cu(gtsm) was more effective against the Chlamydia 98 
elementary bodies compared to Cu(atsm), consistent with earlier observations in N. 99 
gonorrhoeae, Mycobacteria tuberculosis, and Staphylococcus aureus (Speer et al., 2013, 100 
Haeili et al., 2014, Djoko et al., 2015). The ionophores showed similar effects against the RB 101 
phase of a distinct strain of Chlamydia (C. trachomatis L2, data not shown). 102 
It is not yet certain if the Chlamydia reticulate body is completely or partially reliant 103 
on host cell ATP (Tipples & McClarty, 1993, Omsland et al., 2014).  It has been previously 104 
demonstrated that, in addition to the release of bioavailable copper ions into the cytoplasm, 105 
Cu(btsc) complexes partition to the membranes of N. gonorrhoeae where they inhibit the 106 
activity of Nuo and Nqr, two NADH dehydrogenases of the gonococcal electron transport 107 
chain (Djoko et al., 2015). Since Chlamydia possesses an Nqr as its sole NADH 108 
dehydrogenase, it is tempting to suggest that this is potential target for Cu(btsc) complexes in 109 
this bacterium.  110 
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Next we assessed the impact on host cells, by pre-treating McCoy B host cells with 111 
copper complexes 5 hrs prior to infection and then measured the viable infectious yield of 112 
elementary bodies. We observed a loss of chlamydial infectious progeny at 5 µM (Figure 113 
1E), which is a slightly higher dose than the dose leading to loss of infectivity when 114 
compounds were added to chlamydial cultures during the active growth phase. The host cell 115 
live-dead assay (Figure 1D) indicated that in this cell model there was some toxicity that 116 
likely contributed to the phenotypes. Additionally, some EBs were detected at the toxic host 117 
cell concentration of 1.6 µM suggesting that viable EBs are prevailing either in detached host 118 
cell or in the media itself. This host cell effect differs from previous data on different cell 119 
lines where minimal cell death was detected (Djoko et al., 2015), indicating that further 120 
understanding of host cell-specific impacts of copper ionophores is needed before 121 
progressing to in vivo experiments. 122 
The Cu(btsc) complexes, particularly Cu(gtsm), are known to inhibit of Complex I in 123 
isolated rat liver mitochondria (Djoko et al., 2014) but it has not been determined whether 124 
Cu(gtsm) also inhibits mitochondrial function in intact cells and tissues.  Therefore, we 125 
measured cellular respiration to assess whether host cell mitochondrial impacts could explain 126 
the loss of infectious progeny. We measured the impact of Cu(gtsm) and Cu(atsm) on host 127 
cell mitochondrial respiration using the Seahorse XF Cell Mito Stress Test modulators kit 128 
(Agilent Technologies). McCoy B cells were seeded 96-well plates with 20,000 cells per well 129 
and Cu(atsm) and Cu(gtsm) copper complexes were added at 50 and 150 nM for 30 mins 130 
prior to commencing the assay. While Cu(atsm) did not affect the spare respiratory capacity 131 
and ATP production of the host, Cu(gtsm) resulted in a reduction in spare respiratory 132 
capacity at both 50 nM and 150 nM (Figure 1F). Lower doses were tested than those where 133 
complete lethality was observed in Figure 1B as we wished to tease out the role of respiratory 134 
impacts in the doses where loss of progeny was observed.  135 
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In summary, Cu(btsc) were effective against both the intracellular replicative form of 136 
the Chlamydia and the extracellular form. The reduced effect seen following the pre-137 
treatment of EBs (extracellular form) may be attributable to the reduced metabolic activity of 138 
this development form and possible reduced access due to the structural density of the EB 139 
outer membrane. However, given that the copper complexes were also demonstrated to 140 
impact on respiratory capacity of the host cell, it is hard to differentiate the role of host cell 141 
impact from anti-chlamydial impact for loss of chlamydial infectious progeny. It is important 142 
to note, however, that the pre-treatment of host cells is not the same as treatment during an 143 
active infection as the chlamydial burden is likely to alter the respiration rate of the host and 144 
reduce the amount of complex accessing the mitochondria.  145 
These data indicate that these copper compounds are toxic to Chlamydia, although 146 
here a host cell impact is also notable on McCoy B cells that contributed to this phenotype. It 147 
was previously reported that other cells are not susceptible to these compounds (Djoko et al., 148 
2015), suggesting that the toxicity observed in this study may relate to host cell type. Overall, 149 
whilst showing some promise much is needed to be done to unravel toxicity and metabolic 150 
impacts of the copper ionophores on host cells before in vivo applications could be trailed. 151 
Interestingly, these data could suggest that respiration is important for the RB phase of 152 
chlamydial growth. One possible application of future derivatives of these copper complexes 153 
could be as a component of a topical anti-microbial lubricant that could inactivate EBs before 154 
they establish an infection from sexual transmission, and potentially in this application could 155 
minimise any toxicity on the host cells.  156 
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FIGURE 
 
 
Figure 1 A. Structure of Cu(gtsm) and Cu(atsm) molecules. B. Inclusion forming units (IFU) 
produced after C. trachomatis D/UW/3/CX (CtD) cultures were treated with Cu(gtsm) or 
Cu(atsm) at the mid-replicative phase (20 h PI). Infectious progeny were measured at 
completion of the developmental cycle (44 h PI). C. Inclusion forming units after C. 
trachomatis D/UW/3/CX elementary bodies were treated with Cu(gtsm) or Cu(atsm) for 30 
min prior to infection of host cells. Infectious progeny were determined from cultures 
 
 
 
harvested at 44 h PI. D. Live host cell counts after 24 h exposure to Cu(gtsm) or Cu(atsm). E. 
Inclusion forming units after McCoy B host cells were pre-treated with Cu(gtsm) or Cu(atsm) 
prior to the chlamydial infection (for 300 min). A-E. Results are representatives of 
experiments repeated in independent triplicate with n = 27 in each bar. Errors bars depict the 
standard error of the mean. # indicates no growth detected. F. Impact of Cu(gtsm) and 
Cu(atsm) on the basal (energetic demand of the cell under baseline conditions) and spare 
respiratory capacity (capacity of the cell to respond to energetic demands) of the host cells 
when treated in the absence of chlamydial infection (oxygen consumption rate) on the y axis. 
The rate of oxygen consumption was measured following the sequential addition of 
oligomycin (2 µM; targets ATP synthase), carbonyl cyanide-4 
(trifluoromethoxy)phenylhydrazone (2 µM; targets inner mitochondrial membrane), and 
rotenone/antimycin A (0.5 µM; targets complex I and III respectively. Concentrations were 
as per the manufacturer's recommendation. The key to the right indicates the colour 
corresponding to each compound on the graphs. Graphical presentation of the data and 
statistical analysis was conducted using Graphpad Prism (v7).  
